Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Endometrial Cancer 2Thrombosis 1Thrombophilia 1Solid Tumors 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Metastatic Solid Tumors 1Melanoma 1

Interventions

Injections 1Artesunate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Intestinal Neoplasms × Injections × Clear all
NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Cancer Hospital

Phase 1/2 Not yet recruiting
96 enrolled
BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡